Open AccessInterruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection
Author(s) -
Reto Nüesch,
Jintanat Ananworanich,
Preeyaporn Srasuebkul,
Ploenchan Chetchotisakd,
Wisit Prasithsirikul,
Wirat Klinbuayam,
Apicha Mahatharit,
Thidarat Jupimai,
Kiat Ruxrungtham,
Bernard Hirschel
Publication year - 2008
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3282f303bf
Subject(s) - emtricitabine , medicine , hepatitis b virus , virology , tenofovir , lamivudine , hepatitis b , human immunodeficiency virus (hiv) , virus
Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions. HBV replication was suppressed below detection in 15/16 patients. Structured treatment interruption increased transaminases and HBV viraemia in five of six patients; one flare was severe. Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted.